Stockscreener 앱 받기
46.25
1.12%
0.41
전일 마감가:
$45.84
열려 있는:
$45.28
하루 거래량:
124.57K
Relative Volume:
0.06
시가총액:
$5.55B
수익:
$692.26M
순이익/손실:
$-512.41M
주가수익비율:
-10.91
EPS:
-4.24
순현금흐름:
$-274.36M
1주 성능:
+3.66%
1개월 성능:
+10.08%
6개월 성능:
+102.60%
1년 성능:
+158.10%
1일 변동 폭
$44.27
$46.45
1주일 범위
$43.50
$47.72
52주 변동 폭
$15.81
$50.89
가든트헬스 Stock (GH) Company Profile
명칭
Guardant Health Inc
전화
855-698-8887
주소
3100 HANOVER STREET, PALO ALTO
GH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
46.28 | 5.55B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
513.05 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.96 | 150.10B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
419.00 | 34.06B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
119.67 | 34.07B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
179.13 | 31.53B | 15.41B | 1.37B | 2.11B | 7.50 |
가든트헬스 Stock (GH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-28 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-24 | 재개 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-09-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-11-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | 개시 | Craig Hallum | Buy |
| 2022-10-06 | 개시 | Stephens | Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-04-28 | 재개 | BTIG Research | Buy |
| 2022-02-24 | 재확인 | Canaccord Genuity | Buy |
| 2022-02-24 | 재확인 | Citigroup | Buy |
| 2022-02-24 | 재확인 | Cowen | Outperform |
| 2022-02-24 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-24 | 재확인 | SVB Leerink | Outperform |
| 2022-02-24 | 재확인 | Stifel | Buy |
| 2022-02-24 | 재확인 | Wells Fargo | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-11 | 개시 | Stifel | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-06-12 | 개시 | BTIG Research | Buy |
| 2020-02-21 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-08-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-04-16 | 개시 | Canaccord Genuity | Buy |
| 2019-04-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | 재확인 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | JP Morgan | Overweight |
| 2018-10-29 | 개시 | William Blair | Outperform |
모두보기
가든트헬스 주식(GH)의 최신 뉴스
Liquid Biopsy Market Insights and Projections 2025-2032 - openPR
VA expands coverage to include CRC blood test for veterans - Investing.com India
Guardant Health shares rise on VA coverage for cancer test - Investing.com
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries - Yahoo Finance
Key Market Driver in Breast Cancer Liquid Biopsy Industry 2025: Rising Breast Cancer Cases Fuel Demand For ... - WhaTech
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN
Guardant Health director Tariq Musa sells $5,069 in stock By Investing.com - Investing.com South Africa
Guardant Health director Tariq Musa sells $5,069 in stock - Investing.com India
AI Healthcare Co. Accuses Test-Maker Of Infringing Patents - Law360
AI Health Care Co. Accuses Test-Maker Of Infringing Patents - Law360
Creating awareness for Colorectal Cancer Month - WFLA
Guardant Accused of Infringing Tempus AI Cancer Research Tech - Bloomberg Law
Liquid biopsy market flooded with opportunity - BioWorld Online
Guardant Health rises after Medicare ADLT status for colorectal cancer test - MSN
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation - Seeking Alpha
Guardant Health at Barclays Conference: Strategic Expansion in Diagnostics By Investing.com - Investing.com UK
Guardant Health’s ADLT Status Boosts Shield CRC Test’s Market Position and Financial Outlook - TipRanks
1,415 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by SBI Securities Co. Ltd. - Defense World
Investing in Guardant Health (NASDAQ:GH) a year ago would have delivered you a 129% gain - Simply Wall St
Raymond James maintains Guardant Health stock at Outperform By Investing.com - Investing.com Canada
Guardant Health gains ADLT status for CRC blood test By Investing.com - Investing.com Canada
Guardant Health, Inc. Receives ADLT Status From CMS for Shield Blood Test -March 11, 2025 at 07:00 am EDT - Marketscreener.com
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue - Benzinga
Sector Update: Health Care -March 11, 2025 at 01:38 pm EDT - Marketscreener.com
Sector Update: Health Care - TradingView
Guardant Health stock up on Medicare ADLT status (GH:NASDAQ) - Seeking Alpha
Guardant Health Shares Soar After Colorectal Cancer Test Granted ADLT Status -March 11, 2025 at 11:01 am EDT - Marketscreener.com
Citi maintains Buy on Guardant Health, price target at $60 By Investing.com - Investing.com UK
Guardant Health Receives ADLT Status From CMS for Shield Blood Test - 01Net
Guardant Health Says Colorectal Cancer Test Granted ADLT Status -March 11, 2025 at 08:48 am EDT - Marketscreener.com
Guardant Health gains ADLT status for CRC blood test - Investing.com India
Guardant Health Receives ADLT Status From CMS For Shield Blood Test -March 11, 2025 at 07:19 am EDT - Marketscreener.com
When the Price of (GH) Talks, People Listen - Stock Traders Daily
FDA approves blood test for colon cancer detection - MSN
Bank of New York Mellon Corp Reduces Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - Defense World
Morgan Stanley Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock - Defense World
Principal Financial Group Inc. Has $308,000 Stake in Guardant Health, Inc. (NASDAQ:GH) - Defense World
Guardant Health Base Business in 'Fundamentally Good Shape,' Morgan Stanley Says - Marketscreener.com
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
Guardant Health, Inc. (NASDAQ:GH) Short Interest Update - Defense World
Lung Cancer Diagnostics Market Growth | Trends, Size & Forecast 2025-2033 | DSS Imagetec, Abbott, Guardant Health. - openPR
Guardant Health director Joyce sells $4,271 in stock - Investing.com
Morgan Stanley raises Guardant Health target to $52, maintains Overweight - Investing.com India
Guardant Health director Joyce sells $4,271 in stock By Investing.com - Investing.com UK
Guardant Health price target raised to $52 from $42 at Morgan Stanley - TipRanks
LSUHS partners with Dak Prescott to boost colon cancer screening - KTALnews.com
Morgan Stanley raises Guardant Health target to $52, maintains Overweight By Investing.com - Investing.com UK
Morgan Stanley Adjusts Price Target on Guardant Health to $52 From $42, Keeps Overweight Rating - Marketscreener.com
Guardant Health at TD Cowen Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK
Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities - The Bakersfield Californian
Commit To Buy Guardant Health At $32, Earn 17.9% Annualized Using Options - Nasdaq
가든트헬스 (GH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
0.92%
자본화:
|
볼륨(24시간):